BRIEF-Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder

Reuters09-23

Sept 23 (Reuters) - VistaGen Therapeutics Inc :

* VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER

* VISTAGEN THERAPEUTICS INC: NEXT STEP IN REGISTRATION-DIRECTED PALISADE PHASE 3 PROGRAM FOR FASEDIENOL IN SOCIAL ANXIETY DISORDER ACHIEVED AS PLANNED

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2469146631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-23 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469146631","market":"us","top_or_hot":-1,"title":"BRIEF-Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder","media":"Reuters","content":"<html><body><p>Sept 23 (Reuters) - VistaGen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER</p><p>   * VISTAGEN THERAPEUTICS INC: NEXT STEP IN REGISTRATION-DIRECTED PALISADE PHASE 3 PROGRAM FOR FASEDIENOL IN SOCIAL ANXIETY DISORDER ACHIEVED AS PLANNED</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-23 21:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 23 (Reuters) - VistaGen Therapeutics Inc   :   * VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER   * VISTAGEN THERAPEUTICS INC: NEXT ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2469146631","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469146631","pubTimestamp":1727098630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 23  - VistaGen Therapeutics Inc   :   * VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER   * VISTAGEN THERAPEUTICS INC: NEXT STEP IN REGISTRATION-DIRECTED PALISADE PHASE 3 PROGRAM FOR FASEDIENOL IN SOCIAL ANXIETY DISORDER ACHIEVED AS PLANNEDSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTGN":"VistaGen Therapeutics, Inc."},"translate_title":"BRIEF-Vistagen启动Fasedienol急性治疗社交焦虑症的PALISADE-4 3期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTGN":0.9},"content_text":"Sept 23 (Reuters) - VistaGen Therapeutics Inc   :   * VISTAGEN INITIATES PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER   * VISTAGEN THERAPEUTICS INC: NEXT STEP IN REGISTRATION-DIRECTED PALISADE PHASE 3 PROGRAM FOR FASEDIENOL IN SOCIAL ANXIETY DISORDER ACHIEVED AS PLANNEDSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469146631"}